DZ3227A1 - Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees - Google Patents
Compositions pharmaceutiques fournissant des concentrations de medicaments amelioreesInfo
- Publication number
- DZ3227A1 DZ3227A1 DZ003227A DZ003227A DZ3227A1 DZ 3227 A1 DZ3227 A1 DZ 3227A1 DZ 003227 A DZ003227 A DZ 003227A DZ 003227 A DZ003227 A DZ 003227A DZ 3227 A1 DZ3227 A1 DZ 3227A1
- Authority
- DZ
- Algeria
- Prior art keywords
- pharmaceutical compositions
- providing improved
- drug concentrations
- improved drug
- compositions providing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17184199P | 1999-12-23 | 1999-12-23 | |
PCT/IB2000/001787 WO2001047495A1 (fr) | 1999-12-23 | 2000-12-01 | Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees |
Publications (1)
Publication Number | Publication Date |
---|---|
DZ3227A1 true DZ3227A1 (fr) | 2001-07-05 |
Family
ID=22625351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DZ003227A DZ3227A1 (fr) | 1999-12-23 | 2000-12-01 | Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees |
Country Status (39)
Country | Link |
---|---|
US (6) | US8026286B2 (fr) |
EP (3) | EP1239835B1 (fr) |
JP (2) | JP2003518485A (fr) |
KR (1) | KR100558239B1 (fr) |
CN (1) | CN1402629A (fr) |
AP (1) | AP2002002552A0 (fr) |
AR (1) | AR027065A1 (fr) |
AU (1) | AU784340B2 (fr) |
BG (1) | BG106764A (fr) |
BR (1) | BR0016555A (fr) |
CA (1) | CA2395331C (fr) |
CO (1) | CO5261563A1 (fr) |
CR (1) | CR6654A (fr) |
CZ (1) | CZ20022047A3 (fr) |
DZ (1) | DZ3227A1 (fr) |
EA (1) | EA006402B1 (fr) |
EC (1) | ECSP003847A (fr) |
EE (1) | EE200200357A (fr) |
GE (1) | GEP20053427B (fr) |
GT (1) | GT200000219A (fr) |
HR (1) | HRP20020531A2 (fr) |
HU (1) | HUP0204372A3 (fr) |
IL (1) | IL149186A0 (fr) |
IS (1) | IS6344A (fr) |
MA (1) | MA26853A1 (fr) |
MX (1) | MXPA02006324A (fr) |
NO (1) | NO20022998L (fr) |
OA (1) | OA12124A (fr) |
PA (1) | PA8508701A1 (fr) |
PE (1) | PE20010977A1 (fr) |
PL (1) | PL357470A1 (fr) |
SK (1) | SK8562002A3 (fr) |
SV (1) | SV2002000248A (fr) |
TN (1) | TNSN00252A1 (fr) |
TR (1) | TR200201617T2 (fr) |
UY (1) | UY26496A1 (fr) |
WO (1) | WO2001047495A1 (fr) |
YU (1) | YU43702A (fr) |
ZA (1) | ZA200204962B (fr) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
CA2359945C (fr) * | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibiteurs de cristallisation dans une dispersion solide |
BR0016555A (pt) * | 1999-12-23 | 2002-09-17 | Pfizer Prod Inc | Composições farmacêuticas que proporcionam concentrações acrescidas de droga |
US20010053791A1 (en) * | 2000-03-16 | 2001-12-20 | Babcock Walter C. | Glycogen phosphorylase inhibitor |
DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
WO2003000226A2 (fr) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Compositions pharmaceutiques contenant des ensembles polymere et medicament |
EP1269994A3 (fr) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament |
US20030060422A1 (en) | 2001-08-31 | 2003-03-27 | Balaji Venkataraman | Tannate compositions and methods of treatment |
AU2002334987A1 (en) * | 2001-10-15 | 2003-04-28 | The Regents Of The University Of Michigan | Systems and methods for the generation of crystalline polymorphs |
WO2003047595A1 (fr) * | 2001-12-03 | 2003-06-12 | Novacea, Inc. | Compositions pharmaceutiques comprenant des composes actifs de vitamine d |
DE60322665D1 (de) | 2002-02-01 | 2008-09-18 | Pfizer Prod Inc | Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors |
EP1920766B1 (fr) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Compositions pharmaceutiques de dispersions amorphes de médicaments et matériaux formant des microphases lipophiles |
CA2474838C (fr) | 2002-02-01 | 2009-01-06 | Pfizer Products Inc. | Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles |
RU2004123621A (ru) * | 2002-02-01 | 2005-04-10 | Пфайзер Продактс Инк. (Us) | Лекарственные формы с немедленным высвобождением, содержащие твердые дисперсии лекарств |
WO2003082805A1 (fr) | 2002-03-28 | 2003-10-09 | Synthon B.V. | Sels de venlafaxine faiblement solubles dans l'eau |
AU2003226752A1 (en) * | 2002-03-28 | 2003-10-13 | Synthon B.V. | Venlafaxine base |
AU2003221535A1 (en) | 2002-03-28 | 2003-10-13 | Synthon B.V. | Venlafaxine besylate |
RU2005103625A (ru) * | 2002-08-12 | 2005-08-20 | Пфайзер Продактс Инк. (Us) | Фармацевтические композиции полуупорядоченных лекарств и полимеров |
JP2006511475A (ja) | 2002-09-18 | 2006-04-06 | トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア | 脈絡膜新生血管症の抑制方法 |
WO2004050068A1 (fr) | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Compositions pharmaceutiques comprenant un compose medicamenteux respectivement basique, tensioactif et base respectivement acide hydrosoluble et tolerable physiologiquement |
US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
JP4542743B2 (ja) * | 2002-12-26 | 2010-09-15 | Kdl株式会社 | ピリドン誘導体の溶液状医薬組成物 |
OA13050A (en) | 2003-04-29 | 2006-11-10 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension. |
US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
WO2005004763A1 (fr) * | 2003-07-01 | 2005-01-20 | Pharmacia & Upjohn Company Llc. | Formes solides modulees a couche de diffusion |
US20050048118A1 (en) * | 2003-07-25 | 2005-03-03 | Joan Cucala Escoi | Modified release venlafaxine hydrochloride tablets |
BRPI0413277A (pt) * | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas |
US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
AU2004268663B2 (en) * | 2003-09-02 | 2010-12-09 | Pfizer Products Inc. | Sustained release dosage forms of ziprasidone |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
FR2861992B1 (fr) * | 2003-11-10 | 2007-07-20 | Sanofi Synthelabo | Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide. |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
US20050112204A1 (en) * | 2003-11-25 | 2005-05-26 | Pfizer Inc. | Pharmaceutical formulations |
EP1701704A2 (fr) | 2003-12-31 | 2006-09-20 | Pfizer Products Inc. | Compositions solides a base de medicaments peu solubles et de poloxameres |
EP1776089A2 (fr) * | 2003-12-31 | 2007-04-25 | Actavis Group hf | Formulations de donepezil |
US20050163858A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Ziprasidone formulations |
US8436029B2 (en) * | 2004-03-19 | 2013-05-07 | Transform Pharmaceuticals, Inc. | Pharmaceutical forms, and methods of making and using the same |
DK1742950T3 (da) | 2004-04-07 | 2009-03-16 | Pfizer Ltd | Pyrazolo-[4,3-D]-pyrimidiner |
US8158138B1 (en) * | 2004-05-20 | 2012-04-17 | Fougera Pharmaceuticals, Inc. | Urea compositions and their methods of manufacture |
US7776358B2 (en) | 2004-07-22 | 2010-08-17 | Synthon Ip Inc. | Extended release venlafaxine besylate tablets |
JP2008511607A (ja) * | 2004-08-31 | 2008-04-17 | ファイザー・プロダクツ・インク | 低溶解性薬物および重合体を含む医薬投与剤形 |
EP1809329B1 (fr) * | 2004-09-17 | 2011-12-21 | Durect Corporation | Composition locale anesthesique a delivrance soutenue contenant aibs |
EP1844078B1 (fr) * | 2005-02-03 | 2016-09-28 | Bend Research, Inc | Compositions pharmaceutiques a efficacite amelioree |
AU2006213673A1 (en) | 2005-02-09 | 2006-08-17 | Santen Pharmaceutical Co., Ltd. | Formulations for ocular treatment |
US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
US20070287719A1 (en) * | 2005-03-11 | 2007-12-13 | Pfizer Inc | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea |
EP1909762A2 (fr) * | 2005-07-28 | 2008-04-16 | Isp Investments Inc. | Efavirenz amorphe et methode de production |
EP2001438A2 (fr) | 2006-02-09 | 2008-12-17 | Macusight, Inc. | Formulations stables et leurs procedes de preparation et d'utilisation |
JP5506378B2 (ja) | 2006-03-23 | 2014-05-28 | 参天製薬株式会社 | 血管透過性に関連する疾患または病気のための製剤および方法 |
US8900619B2 (en) | 2006-08-24 | 2014-12-02 | Boston Scientific Scimed, Inc. | Medical devices for the release of therapeutic agents |
EP2081554A2 (fr) * | 2006-09-27 | 2009-07-29 | Dr. Reddy's Laboratories Ltd. | Compositions pharmaceutiques d'atorvastatine |
US20080085315A1 (en) * | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
EP1920767A1 (fr) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Forme posologique d'Imatinib préparée à l'état fondu. |
US20080152717A1 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments, Inc. | Amorphous valsartan and the production thereof |
US8613946B2 (en) * | 2006-12-21 | 2013-12-24 | Isp Investment Inc. | Carotenoids of enhanced bioavailability |
US20080181961A1 (en) * | 2007-01-26 | 2008-07-31 | Isp Investments, Inc. | Amorphous oxcarbazepine and the production thereof |
EP2125938A2 (fr) * | 2007-01-26 | 2009-12-02 | Isp Investments Inc. | Procédé de traitement de formulation pour produire des produits séchés pour une pulvérisation |
US20100266692A1 (en) * | 2007-07-13 | 2010-10-21 | Corey Jay Bloom | Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer |
WO2009100176A2 (fr) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase |
WO2009114365A2 (fr) * | 2008-03-13 | 2009-09-17 | Mallinckrodt Inc. | Dispositif de commande multifonctions actionné à l'aide du pied pour système d'imagerie |
US11304960B2 (en) * | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
CA2761389A1 (fr) | 2009-02-05 | 2010-08-12 | Tokai Pharmaceuticals, Inc. | Nouveaux promedicaments a base d'inhibiteurs cyp17 steroidiens/anti-androgenes |
SI2442791T1 (sl) | 2009-06-16 | 2020-03-31 | Pfizer Inc. | Dozirna oblika apiksabana |
WO2011068403A2 (fr) | 2009-12-02 | 2011-06-09 | Ultimorphix Technologies B.V. | Nouveaux sels de n-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine |
SI2586426T1 (sl) | 2009-12-03 | 2015-11-30 | Alcon Research Ltd. | Suspenzije nanodelcev, ki vsebujejo karboksivinilni polimer |
US20130108701A1 (en) | 2010-05-25 | 2013-05-02 | Krishna Murthy Bhavanasi | Solid Dosage Forms of Antipsychotics |
US20120015913A1 (en) * | 2010-07-15 | 2012-01-19 | Delansorne Remi | Formulations of 14-EPI-Analogues of Vitamin D |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
ES2645769T3 (es) | 2011-01-05 | 2017-12-07 | Hospira, Inc. | Secado por pulverización de la vancomicina |
AU2012225459A1 (en) | 2011-03-08 | 2013-10-10 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠(olopatadine)眼用組成物 |
US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
JP5879803B2 (ja) * | 2011-08-08 | 2016-03-08 | ライオン株式会社 | 固形医薬組成物、その製造方法及び医薬製剤 |
RU2759837C2 (ru) * | 2012-05-31 | 2021-11-18 | Мерк Шарп И Доум Корп. | Составы твердых дозированных лекарственных форм антагониста орексинового рецептора |
MX358097B (es) | 2012-09-26 | 2018-08-06 | Pfizer | Formulaciones liquidas de apixaban. |
EA028481B1 (ru) | 2012-10-18 | 2017-11-30 | Эббви Инк. | Препараты производных пиримидиндиона |
US9492550B2 (en) | 2013-03-01 | 2016-11-15 | Hercules Llc | Pharmaceutical compositions with enhanced performance and improved processability |
EP4066841A1 (fr) | 2013-03-14 | 2022-10-05 | University of Maryland, Baltimore | Agents de diminution du récepteur des androgènes et leurs utilisations |
US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
AU2014296314B2 (en) * | 2013-07-30 | 2017-07-27 | Gilead Connecticut, Inc. | Formulation of Syk inhibitors |
AU2014306698A1 (en) | 2013-08-12 | 2016-01-28 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
EP3089757A1 (fr) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Formes galéniques antivirales solides |
TW201613579A (en) | 2014-06-24 | 2016-04-16 | Astellas Pharma Inc | Pharmaceutical composition for oral administration |
WO2016033549A2 (fr) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
WO2017035408A1 (fr) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Composés pour le traitement de troubles immunitaires et inflammatoires |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
SG11201808949SA (en) | 2016-04-15 | 2018-11-29 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
KR20190036520A (ko) | 2016-06-27 | 2019-04-04 | 아칠리온 파르마세우티칼스 인코포레이티드 | 의학적 장애를 치료하기 위한 퀴나졸린 및 인돌 화합물 |
EP3544614A4 (fr) | 2016-11-28 | 2020-08-05 | Lipocine Inc. | Traitement oral à base d'undécanoate de testostérone |
KR102117677B1 (ko) * | 2018-03-08 | 2020-06-01 | (주)이엘티사이언스 | 용해도가 개선된 축산용 삼종염 소독제 복합조성물 |
WO2019175657A1 (fr) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Schéma posologique de modulateur d'assemblage de capside |
CN112004529B (zh) | 2018-04-06 | 2023-08-08 | 比利时胶囊公司 | 包含聚[(甲基丙烯酸甲酯)-共-(甲基丙烯酸)]的低纵横比颗粒的喷雾干燥方法 |
EP3793527A1 (fr) * | 2018-05-14 | 2021-03-24 | Capsugel Belgium NV | Formes posologiques solides à chargement d'agent actif élevé |
US11517548B2 (en) * | 2018-07-19 | 2022-12-06 | Impel Pharmaceuticals Inc. | Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease |
EP3841086A4 (fr) | 2018-08-20 | 2022-07-27 | Achillion Pharmaceuticals, Inc. | Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément |
WO2020081723A1 (fr) | 2018-10-16 | 2020-04-23 | Georgia State University Research Foundation, Inc. | Promédicaments de monoxyde de carbone pour le traitement de troubles médicaux |
WO2020172431A1 (fr) | 2019-02-22 | 2020-08-27 | Gilead Sciences, Inc. | Formes solides de pyrazines condensées en tant qu'inhibiteur de syk |
US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
JP7188364B2 (ja) * | 2019-11-25 | 2022-12-13 | トヨタ自動車株式会社 | 車椅子乗客拘束構造 |
CN115666621A (zh) | 2020-01-13 | 2023-01-31 | 度勒科特公司 | 具有减少的杂质的持续释放药物递送系统及相关方法 |
WO2024012361A1 (fr) * | 2022-07-11 | 2024-01-18 | 江苏恩华药业股份有限公司 | Injection d'émulsion de graisse d'alphaxalone et son procédé de préparation |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4344934A (en) | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
CA1146866A (fr) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Procede de production d'un compose pharmaceutique a liberation continue sous forme solide |
US4301146A (en) | 1980-07-29 | 1981-11-17 | G. D. Searle & Co. | Stabilization of 16-oxygenated prostanoic acid derivatives |
US4321253A (en) | 1980-08-22 | 1982-03-23 | Beatty Morgan L | Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration |
DE3224619A1 (de) | 1981-07-14 | 1983-05-19 | Freund Industrial Co., Ltd., Tokyo | Orale pharmazeutische zusammensetzung |
FR2525108B1 (fr) | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
US4461759A (en) * | 1983-01-03 | 1984-07-24 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulations of veropamil |
US4933360A (en) | 1983-03-16 | 1990-06-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel chlorthalidone process and product |
US4517179A (en) | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
IT1187751B (it) | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
IE63321B1 (en) | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
JPS6314724A (ja) | 1986-07-08 | 1988-01-21 | Tooa Eiyoo Kk | プラゾシン製剤 |
PH26518A (en) | 1987-11-11 | 1992-08-07 | Fujisawa Pharmaceutical Co | A novel pharmaceutical composition comprising exifone and water-soluble polymer |
IE60383B1 (en) | 1988-05-27 | 1994-07-13 | Elan Corp Plc | Controlled release pharmaceutical formulation |
JP2528706B2 (ja) * | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
US5368864A (en) | 1988-11-25 | 1994-11-29 | Henning Berlin Gmbh Chemie- Und Pharmawerk | Formulation of oxypurinol and/or its alkali and alkaline earth salts |
JPH02149518A (ja) | 1988-11-30 | 1990-06-08 | Nikken Chem Co Ltd | 経口投与用薬剤 |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
CA2020654A1 (fr) * | 1989-07-07 | 1991-01-08 | Yohko Akiyama | Compose fgf stabilise et sa production |
US5035897A (en) | 1989-09-05 | 1991-07-30 | Alza Corporation | Dosage form for delivering soluble or insoluble drugs |
JP2939491B2 (ja) * | 1989-12-11 | 1999-08-25 | 株式会社アドバンス | 機能性食品 |
JP2558396B2 (ja) | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
WO1992001453A1 (fr) | 1990-07-19 | 1992-02-06 | Otsuka Pharmaceutical Co., Ltd. | Preparation solide |
US5292520A (en) | 1990-09-13 | 1994-03-08 | Akzo N.V. | Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer |
US5102668A (en) | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
EP0482948A1 (fr) | 1990-10-26 | 1992-04-29 | Asahi Kasei Kogyo Kabushiki Kaisha | Médicament à base de dérivés d'alkoxyquinoxaline substitués en position 6 et procédé de préparation |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
DE69222847T3 (de) | 1991-04-16 | 2005-09-15 | Nippon Shinyaku Co., Ltd. | Verfahren zur herstellung einer festen dispersion |
HU222501B1 (hu) | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
JP2881519B2 (ja) | 1991-07-09 | 1999-04-12 | 中塚工業 株式会社 | 艶消し立体模様箔糸原反の製造法 |
US5225204A (en) | 1991-11-05 | 1993-07-06 | Chen Jivn Ren | Stable dosage of levothyroxine sodium and process of production |
DK89592D0 (da) | 1992-07-07 | 1992-07-07 | Helle Broendsted | Laegemiddelafgivelsesindretning samt fremgangsmaade til fremstilling deraf |
US5811547A (en) | 1992-10-14 | 1998-09-22 | Nippon Shinyaju Co., Ltd. | Method for inducing crystalline state transition in medicinal substance |
JPH06128147A (ja) * | 1992-10-20 | 1994-05-10 | Masayasu Sugihara | 水難溶性薬品の溶解性改善方法およびそれにより得られた薬品組成物 |
JPH06314724A (ja) | 1993-04-28 | 1994-11-08 | Hitachi Cable Ltd | 半導体素子搭載用両面配線基板,及びそれを用いた半導 体装置 |
JP2916978B2 (ja) * | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5972383A (en) | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
WO1996019239A1 (fr) | 1994-12-21 | 1996-06-27 | Yamanouchi Pharmaceutical Co., Ltd. | Composition solide a solubilite et absorbabilite ameliorees |
US5716642A (en) | 1995-01-10 | 1998-02-10 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents |
US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
EP0814774B1 (fr) * | 1995-03-24 | 2005-10-19 | Genzyme Corporation | Diminution des adherences par liberation controlee d'inhibiteurs d'oxygene actif |
US5654005A (en) | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
ATE240734T1 (de) | 1995-07-26 | 2003-06-15 | Kyowa Hakko Kogyo Kk | Zubereitung von xanthinderivaten als feste dispersion |
GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
TW487582B (en) | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
DE19531684A1 (de) | 1995-08-29 | 1997-03-06 | Bayer Ag | Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
JPH09309828A (ja) | 1996-03-18 | 1997-12-02 | Eisai Co Ltd | 溶解を改善した薬剤組成物 |
EP0904273B1 (fr) * | 1996-05-07 | 2003-04-09 | Pfizer Inc. | Trihydrate du sel mesylate de 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), sa preparation et son utilisation en tant qu'antagoniste du recepteur dopaminergique d2 |
JPH107558A (ja) | 1996-06-19 | 1998-01-13 | Eisai Co Ltd | 溶解性改善製剤 |
EP0826685A1 (fr) * | 1996-08-21 | 1998-03-04 | Pfizer Inc. | Sels de carboxamides stables à effet prolongé destinés au traitement des maladies articulaires |
ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
EP0837063A1 (fr) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | Dérivés de 4-aminoquinazoline |
US5977158A (en) | 1996-11-28 | 1999-11-02 | Novo Nordisk A/S | Pharmaceutical formulations comprising levormeloxifene compounds |
CA2290974C (fr) | 1997-07-01 | 2004-04-27 | Pfizer Products Inc. | Compositions de sertraline solubilisee |
DK0901786T3 (da) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
HN1998000115A (es) | 1997-08-21 | 1999-06-02 | Warner Lambert Co | Formas de dosificación farmacéuticas sólidas |
CA2273272C (fr) * | 1997-10-07 | 2004-09-21 | Fuisz Technologies Ltd. | Formes galeniques pour l'administration de medicaments a liberation immediate |
US6110502A (en) | 1998-02-19 | 2000-08-29 | Mcneil-Ppc, Inc. | Method for producing water dispersible sterol formulations |
BR9910481A (pt) | 1998-06-11 | 2001-01-09 | Upjohn Co | Composição farmacêutica para comprimido de liberação não-contìnua |
ES2157731B1 (es) | 1998-07-21 | 2002-05-01 | Liconsa Liberacion Controlada | Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. |
EP2266542A3 (fr) | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Libération regulée de compositions nanoparticulaires |
EP1027885B1 (fr) * | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Compositions de médicaments basiques avec une meilleure biodisponibilité |
ES2307482T3 (es) | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
ES2310164T3 (es) * | 1999-02-10 | 2009-01-01 | Pfizer Products Inc. | Dispositivo de liberacion controlada por la matriz. |
ATE433318T1 (de) | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
CA2362816C (fr) | 1999-12-08 | 2007-02-06 | Pharmacia Corporation | Compositions de valdecoxib |
EP1150959B1 (fr) | 1999-12-08 | 2008-02-27 | Pharmacia Corporation | Forme solide de celecoxib, presentant une biodisponibilite accrue |
BR0016555A (pt) * | 1999-12-23 | 2002-09-17 | Pfizer Prod Inc | Composições farmacêuticas que proporcionam concentrações acrescidas de droga |
AR027656A1 (es) * | 2000-03-16 | 2003-04-09 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
-
2000
- 2000-12-01 BR BR0016555-7A patent/BR0016555A/pt not_active Application Discontinuation
- 2000-12-01 CN CN00816563A patent/CN1402629A/zh active Pending
- 2000-12-01 AU AU14091/01A patent/AU784340B2/en not_active Ceased
- 2000-12-01 EP EP00976217A patent/EP1239835B1/fr not_active Expired - Lifetime
- 2000-12-01 IL IL14918600A patent/IL149186A0/xx unknown
- 2000-12-01 EA EA200200431A patent/EA006402B1/ru not_active IP Right Cessation
- 2000-12-01 WO PCT/IB2000/001787 patent/WO2001047495A1/fr not_active Application Discontinuation
- 2000-12-01 KR KR1020027008138A patent/KR100558239B1/ko not_active IP Right Cessation
- 2000-12-01 EE EEP200200357A patent/EE200200357A/xx unknown
- 2000-12-01 DZ DZ003227A patent/DZ3227A1/fr active
- 2000-12-01 AP APAP/P/2002/002552A patent/AP2002002552A0/en unknown
- 2000-12-01 EP EP06117018A patent/EP1738749A1/fr not_active Ceased
- 2000-12-01 CZ CZ20022047A patent/CZ20022047A3/cs unknown
- 2000-12-01 EP EP06117015A patent/EP1712222A3/fr not_active Withdrawn
- 2000-12-01 YU YU43702A patent/YU43702A/sh unknown
- 2000-12-01 HU HU0204372A patent/HUP0204372A3/hu unknown
- 2000-12-01 SK SK856-2002A patent/SK8562002A3/sk unknown
- 2000-12-01 MX MXPA02006324A patent/MXPA02006324A/es active IP Right Grant
- 2000-12-01 PL PL00357470A patent/PL357470A1/xx not_active Application Discontinuation
- 2000-12-01 GE GE4831A patent/GEP20053427B/en unknown
- 2000-12-01 CA CA002395331A patent/CA2395331C/fr not_active Expired - Fee Related
- 2000-12-01 TR TR2002/01617T patent/TR200201617T2/xx unknown
- 2000-12-01 OA OA1200200191A patent/OA12124A/en unknown
- 2000-12-01 JP JP2001548090A patent/JP2003518485A/ja active Pending
- 2000-12-13 PA PA20008508701A patent/PA8508701A1/es unknown
- 2000-12-14 CO CO00095393A patent/CO5261563A1/es not_active Application Discontinuation
- 2000-12-20 UY UY26496A patent/UY26496A1/es not_active Application Discontinuation
- 2000-12-20 US US09/742,785 patent/US8026286B2/en not_active Expired - Fee Related
- 2000-12-21 EC EC2000003847A patent/ECSP003847A/es unknown
- 2000-12-21 GT GT200000219A patent/GT200000219A/es unknown
- 2000-12-21 AR ARP000106852A patent/AR027065A1/es unknown
- 2000-12-21 PE PE2000001384A patent/PE20010977A1/es not_active Application Discontinuation
- 2000-12-22 TN TNTNSN00252A patent/TNSN00252A1/fr unknown
- 2000-12-22 SV SV2000000248A patent/SV2002000248A/es unknown
-
2002
- 2002-04-16 IS IS6344A patent/IS6344A/is unknown
- 2002-05-31 BG BG106764A patent/BG106764A/bg unknown
- 2002-06-04 CR CR6654A patent/CR6654A/es not_active Application Discontinuation
- 2002-06-13 MA MA26687A patent/MA26853A1/fr unknown
- 2002-06-18 HR HR20020531A patent/HRP20020531A2/hr not_active Application Discontinuation
- 2002-06-20 ZA ZA200204962A patent/ZA200204962B/en unknown
- 2002-06-21 NO NO20022998A patent/NO20022998L/no not_active Application Discontinuation
-
2007
- 2007-11-01 JP JP2007285190A patent/JP2008101004A/ja not_active Withdrawn
-
2011
- 2011-08-11 US US13/208,305 patent/US8202912B2/en not_active Expired - Lifetime
-
2012
- 2012-06-19 US US13/527,536 patent/US8501231B2/en not_active Expired - Fee Related
-
2013
- 2013-06-11 US US13/915,311 patent/US8796341B2/en not_active Expired - Fee Related
-
2014
- 2014-07-14 US US14/331,172 patent/US8980321B2/en not_active Expired - Fee Related
-
2015
- 2015-03-16 US US14/659,271 patent/US9457095B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DZ3227A1 (fr) | Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees | |
NO20022970D0 (no) | Hydrogel-drevet medikamentdoseringsform | |
FR2795324B1 (fr) | Compositions pharmaceutiques stabilisees | |
NO20020464L (no) | Flerkomponents farmasöytisk doseringsform | |
PT1221918E (pt) | Administracao de drogas sub-tenon | |
FR2775596B1 (fr) | Nouvelles compositions pharmaceutiques | |
EE04901B1 (et) | Peroraalne farmatseutiline pikendatud vabanemisega annusvorm | |
NO20015175D0 (no) | Farmasöytisk sammensetning | |
NO20030627L (no) | Hydrogel-drevet medikament doseringsform | |
NO20014035D0 (no) | System for oral administrasjon av medikament | |
IL164699A (en) | Derivatives of diketohydrazine compounds and pharmaceutical compositions and medicaments containing the compounds as the active ingredient | |
NO20015670D0 (no) | Forbedrede farmasöytiske formuleringer | |
EE200200075A (et) | Peroraalselt ja paikselt manustatavad farmatseutilised kompositsioonid | |
NO20014738D0 (no) | Tolperisonholdig farmasöytisk preparat for oral administrering | |
FR2802423B1 (fr) | Compositions pharmaceutiques | |
FR2792529B1 (fr) | Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines | |
NO20021898D0 (no) | Farmasöytisk sammensetning inneholdende ciclesonid for applikasjon til mukosa | |
ATE270107T1 (de) | Ciclesonidhaltige wässrige arzneizusammensetzungen | |
FI4488U1 (fi) | Farmaseuttinen koostumus | |
FR2797444B1 (fr) | Compositions pharmaceutiques comprenant des 4-quinolones | |
FR2779145B1 (fr) | Nouvelles compositions pharmaceutiques | |
AR025867A1 (es) | Formulacion portasdora farmaceutica | |
AU2001260089A1 (en) | Pharmaceutical compositions comprising desglymidodrine as an active drug substance | |
ATE338548T1 (de) | Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen | |
HUP0303089A3 (en) | Stable pharmaceutical form of an anticancer drug |